Educational content only. Not medical advice. Consult a qualified physician.
Bremelanotide peptide
Sexual HealthFDA-approved (Vyleesi) for HSDD in premenopausal women. Off-label use in men and for other indications is not FDA-approved.

PT-141

Bremelanotide

PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist that acts on the MC3R and MC4R receptors in the central nervous system. Unlike PDE5 inhibitors that act on vascular mechanisms, PT-141 works through the brain's arousal pathways. It is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Reported Benefits

Potential Benefits

  • FDA-approved for hypoactive sexual desire disorder in premenopausal women
  • Acts through central nervous system arousal pathways rather than peripheral vascular effects
  • Clinical trials demonstrated increased sexual desire and reduced distress related to low desire
  • May benefit both men and women based on earlier clinical research
  • Does not require ongoing daily dosing; used on-demand
Research Dosing

Recommended Starting Dose

1.75 mg subcutaneously (FDA-approved dose for HSDD)

Based on published research protocols. Not a prescription.

Dosing Protocol

FDA-approved dosing is 1.75 mg subcutaneously in the abdomen or thigh, administered at least 45 minutes before anticipated sexual activity. No more than one dose per 24 hours and no more than 8 doses per month. Lower doses (500 mcg-1 mg) are sometimes used off-label.

DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.

Research Timeline

Expected Timeline

Phase 1

Effects typically begin within 45 minutes to 2 hours after injection and may last several hours.

Regulatory

Research Status

FDA-approved (Vyleesi) for HSDD in premenopausal women. Off-label use in men and for other indications is not FDA-approved.

The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.

Safety Profile

Potential Side Effects

  • Nausea (most common, reported in ~40% of clinical trial participants)
  • Flushing
  • Headache
  • Injection site reactions
  • Transient increase in blood pressure
  • Skin hyperpigmentation with repeated use
  • Not recommended for use more than once every 24 hours or more than 8 times per month
Related Research

More in Sexual Health

Medical Disclaimer

EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.